On December 10, 2021 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, reported that updated data from its lead KRAS-mutated metastatic colorectal cancer program will be featured in a poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO-GI) (Press release, Cardiff Oncology, DEC 10, 2021, View Source [SID1234596750]). ASCO (Free ASCO Whitepaper)-GI is taking place January 20-22, 2022, both virtually and in-person at the Moscone West Building in San Francisco, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the poster and its corresponding abstract can be found below.

Title: A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)
Abstract Number: 100
Abstract Publication Date: January 18, 2022
Abstract Publication Time: 5:00 PM ET
Poster Session Name: Poster Session C: Cancers of the Colon, Rectum, and Anus
Poster Session Date: January 22, 2022
Poster Session Time: 9:30 AM – 10:55 AM ET
Poster Session Location: Level 1, West Hall (and online)

A copy of the poster will be available on the "Scientific Presentations" section of the Cardiff Oncology website at View Source following its presentation at the meeting.